Cargando…

Paradoxical Procoagulant Effect of Early Doses of Warfarin: Possible Role of Non-Vitamin K Oral Anticoagulant in Patients with Atrial Fibrillation-Related Stroke

Detalles Bibliográficos
Autores principales:	Kim, Yesel, Bang, Oh Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Stroke Society 2015
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460341/ https://www.ncbi.nlm.nih.gov/pubmed/26060809 http://dx.doi.org/10.5853/jos.2015.17.2.216

Ejemplares similares

Asian Patients with Stroke plus Atrial Fibrillation and the Dose of Non-Vitamin K Oral Anticoagulants
por: Bang, Oh Young, et al.
Publicado: (2016)

Anticoagulation for Atrial Fibrillation in Cirrhosis of the Liver: Are Low‐Dose Non‐Vitamin K Oral Anticoagulants a Reasonable Alternative to Warfarin?
por: Gallagher, Celine, et al.
Publicado: (2019)

Ten years of non-vitamin K antagonists oral anticoagulants for stroke prevention in atrial fibrillation: is warfarin obsolete?
por: Hammwöhner, Matthias, et al.
Publicado: (2020)

Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation
por: Friberg, Leif, et al.
Publicado: (2017)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage
por: Nielsen, Peter Brønnum, et al.
Publicado: (2019)

Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin
Publicado: (2020)

Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin
por: Huang, Huei‐Kai, et al.
Publicado: (2020)

Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
por: de Padua Mansur, Antonio, et al.
Publicado: (2012)

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)

Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
por: Lee, Hsin‐Fu, et al.
Publicado: (2019)

Cardiovascular and renal protective effects of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation
por: Choi, Seong Huan, et al.
Publicado: (2022)

Occurrence of Ischemic Stroke in Patients With Atrial Fibrillation Receiving Non-Vitamin K Oral Anticoagulants: Causes and Prevention Strategies
por: Bang, Oh Young, et al.
Publicado: (2023)

Real-world comparison of non-vitamin K antagonist oral anticoagulants and warfarin in Asian octogenarian patients with atrial fibrillation
por: Kwon, Chang Hee, et al.
Publicado: (2016)

Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
por: Nielsen, Peter Brønnum, et al.
Publicado: (2017)

Quality of Anticoagulation with Warfarin in Korean Patients with Atrial Fibrillation and Prior Stroke: A Multicenter Retrospective Observational Study
por: Hong, Keun-Sik, et al.
Publicado: (2017)

Meta-analysis of the efficacy and safety of non-vitamin K antagonist oral anticoagulants with warfarin in Latin American patients with atrial fibrillation
por: Su, Zhiyu, et al.
Publicado: (2020)

Safety and efficacy of non–vitamin K antagonist oral anticoagulants compared with well-controlled warfarin in Thai patients with atrial fibrillation
por: Yamkasikorn, Janekij, et al.
Publicado: (2022)

Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation
por: Bisson, Arnaud, et al.
Publicado: (2017)

Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

Impact of Reduced-Dose Nonvitamin K Antagonist Oral Anticoagulants on Outcomes Compared to Warfarin in Korean Patients with Atrial Fibrillation: A Nationwide Population-Based Study
por: Han, Sola, et al.
Publicado: (2021)

Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: Lee, Ki Hong, et al.
Publicado: (2023)

Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks
por: Deitelzweig, Steve, et al.
Publicado: (2013)

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients without previous oral anticoagulants or stable under warfarin: a nationwide cohort study
por: Liu, Shin-Huei, et al.
Publicado: (2023)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta‐Analysis
por: Deng, Yuqing, et al.
Publicado: (2019)

Non-vitamin K antagonist oral anticoagulants versus warfarin for cardioversion of atrial fibrillation in clinical practice: A single-center experience
por: Shibata, Naoki, et al.
Publicado: (2017)

Real‐life experience with non‐vitamin K antagonist oral anticoagulants versus warfarin in patients undergoing elective cardioversion of atrial fibrillation
por: Itäinen‐Strömberg, Saga, et al.
Publicado: (2020)

Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study
por: Halvorsen, Sigrun, et al.
Publicado: (2021)

Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants
por: Caturano, Alfredo, et al.
Publicado: (2019)

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
por: Choi, Jiyoon C, et al.
Publicado: (2014)

Inadequate oral anticoagulation with warfarin in women with cerebrovascular event and history of atrial fibrillation: the FibStroke study
por: Bah, Aissa, et al.
Publicado: (2021)

Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study
por: Calkins, Hugh, et al.
Publicado: (2019)

Veterans Perceptions of Satisfaction and Convenience with Anticoagulants for Atrial Fibrillation: Warfarin versus Direct Oral Anticoagulants
por: Mull, Hillary J, et al.
Publicado: (2020)

Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
por: Larsen, Torben Bjerregaard, et al.
Publicado: (2016)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Asians With Atrial Fibrillation: Meta-Analysis of Randomized Trials and Real-World Studies
por: Xue, Zhengbiao, et al.
Publicado: (2019)

Effectiveness and Safety of Off-label Dosing of Non–vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients
por: Lee, Kwang-No, et al.
Publicado: (2020)

The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis
por: Bang, Oh Young, et al.
Publicado: (2020)

Risk of recurrent stroke for Asian stroke patients treated with non-vitamin K antagonist oral anticoagulant and warfarin
por: Lin, Sheng-Feng, et al.
Publicado: (2020)

Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation
por: Zawawi, Nur Azyyati, et al.
Publicado: (2021)

Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention
por: Zulkifly, Hanis, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dgd0qik09mr4t6811nq5ahroe4